论文部分内容阅读
免疫球蛋白在临床上应用已有几十年的历史。普通免疫球蛋白制剂因含有聚合的大分子,抗补体活性高,不能用于静注。为满足临床上日益广泛的需要,相继出现了酶解免疫球蛋白、磺化免疫球蛋白及聚乙二醇分离的免疫球蛋白等静注用免疫球蛋白制剂,并已在临床上应用。但它们存在一个共同问题,就是缺乏特异性抗体。因此,特异人免疫球蛋白制剂在临床上的应用将会日益增加,并可期待单克隆抗体在免疫球蛋白制剂方面的应用。
Immunoglobulins have been used clinically for decades. Ordinary immunoglobulin preparations contain polymeric macromolecules, anti-complement activity is high, can not be used for intravenous injection. In order to meet the increasingly widespread clinical needs, have emerged enzymolysis immunoglobulin, sulfonated immunoglobulin and polyethylene glycol isolation of immunoglobulin and other intravenous immunoglobulin preparations, and has been in clinical application. But they have a common problem, that is, the lack of specific antibodies. Therefore, the clinical application of specific human immunoglobulin preparations will increase, and the application of monoclonal antibodies in immunoglobulin preparations is expected.